Advertisement

Cannabinoids in the Management of Nausea and Vomiting

  • Linda A. Parker
  • Cheryl L. Limebeer

With the discovery of the endocannabinoid system, research investigating the role that this system plays in the control of nausea and vomiting has accelerated. In this chapter, we review some of the evidence in both human clinical trials literature and animal literature demonstrating the potential of cannabinoids to modify nausea and vomiting.

Keywords

Antiemetic Effect Anticipatory Nausea Dorsal Vagal Complex Taste Reactivity Flavored Solution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aapro MS, Kirchner V, Terrey JP (1994) The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 69:957–960.PubMedGoogle Scholar
  2. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research (2003) A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14:291–297.CrossRefGoogle Scholar
  3. Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56:2097–2102.CrossRefPubMedGoogle Scholar
  4. Andrews PLR, Davis CJ (1995) The physiology of emesis induced by anti-cancer therapy. In: Reynolds J, Andrews PLR, Davis CJ (eds.), Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford: Oxford Clinical Communications, pp. 25–41.Google Scholar
  5. Andrews PLR, Horn CC (2006) Signals for nausea and emesis: implications for models diseases. Auton Neurosci 125:100–115.CrossRefPubMedGoogle Scholar
  6. Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46.CrossRefPubMedGoogle Scholar
  7. Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharm 137:589–96.CrossRefGoogle Scholar
  8. Bartlett N, Koczwara B (2002) Control of nausea and vomiting after chemotherapy: what is the evidence? Intern Med J 32:401–407.CrossRefPubMedGoogle Scholar
  9. Billig I, Yates BJ, Rinaman L (2001) Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol 281:R1243–R1255.PubMedGoogle Scholar
  10. Borrison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5:193–230.Google Scholar
  11. Breslin PA, Spector AC, Grill HJ (1992) A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci 106:820–836.CrossRefPubMedGoogle Scholar
  12. Carey MP, Burish TG, Brenner DE (1983) Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99:106–114.PubMedGoogle Scholar
  13. Carrier EJ, Achampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103:7895–7900.CrossRefPubMedGoogle Scholar
  14. Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25:959–961.CrossRefPubMedGoogle Scholar
  15. Crawford SM, Buckman R (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatin: a double blind study. Med Oncol Tumor Pharmacother 3:39–42.PubMedGoogle Scholar
  16. Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA (2007) Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology 190:135–143.CrossRefPubMedGoogle Scholar
  17. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24:685–689.CrossRefPubMedGoogle Scholar
  18. Darmani NA (2001a) Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24:198–203.CrossRefPubMedGoogle Scholar
  19. Darmani NA (2001b) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharmacol Biochem Behav 69:239–249.CrossRefPubMedGoogle Scholar
  20. Darmani NA (2001c) The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55212–2. Eur J Pharm 430:49–58.CrossRefGoogle Scholar
  21. Darmani NA (2002) The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Delta9-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 300:34–42.CrossRefPubMedGoogle Scholar
  22. Darmani NA, Johnson CJ (2004) Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488:201–212.CrossRefPubMedGoogle Scholar
  23. Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75:777–787.CrossRefPubMedGoogle Scholar
  24. Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, Di Marzo V (2005) Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 49:502–513.CrossRefPubMedGoogle Scholar
  25. Davey VA, Biederman GB (1998) Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. J Exp Psychol Anim Behav Process 24:483–491.CrossRefPubMedGoogle Scholar
  26. Domjan M (1977) Selective suppression of drinking during a limited period following aversive drug treatment in rats. J Exp Psychol Anim Behav Process 3:66–76.CrossRefPubMedGoogle Scholar
  27. Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73:907–910.PubMedGoogle Scholar
  28. Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R (1989) Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 4:159–165.CrossRefGoogle Scholar
  29. Ferrari F, Ottanik A, Giuliani D (1999) Cannabimimetic activity in rats and pigeons of HU-210, a potent antiemetic drug. Pharmacol Biochem Behav 62:75–80.CrossRefPubMedGoogle Scholar
  30. Garcia J, Rusiniak KW, Brett LP (1977) Conditioning food-illness aversions in wild animals: caveant canonici. In: Davis H, Hurowitz HMB (eds.), Operant Pavlovian Interactions. Hillsdale, NJ: Lawrence Erlbaum, pp. 273–316.Google Scholar
  31. Grelot L, Milano S, LeStunff H (1995) Does 5-HT play a role in the delayed phase of cisplatin-induced emesis? In: Reynolds J, Andrews PLR, Davis CJ (eds.), Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford: Oxford Clinical Communications, pp. 181–191.Google Scholar
  32. Grill HC, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143:263–279.CrossRefPubMedGoogle Scholar
  33. Grinspoon L, Bakalar JB (1993) Marijuana: The Forbidden Medicine. New Haven: Yale University Press.Google Scholar
  34. Gylys JA, Doran KM, Buyniski PJ (1979) Antagonism of cisplatin induced emesis in the dog. Res Commun Chem Pathol Pharmacol 23:61–68.PubMedGoogle Scholar
  35. Hall W, Christie M, Currow D (2005) Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6:35–42.PubMedGoogle Scholar
  36. Hampson AJ, Grimaldi M, Axelrod J (1998) Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268–8273.CrossRefPubMedGoogle Scholar
  37. Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451–460.CrossRefPubMedGoogle Scholar
  38. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074–1080.CrossRefPubMedGoogle Scholar
  39. Hickok JT., Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-Hydroxytryptamine-3 antiemetics. Cancer 97:2880–2886.CrossRefPubMedGoogle Scholar
  40. Hillsley K, Grundy D (1998) Serotonin and cholecystokinin activate different populations of rat mesenteric vagal afferents. Neurosci Lett 255:63–66.CrossRefPubMedGoogle Scholar
  41. Himmi T, Dallaporta M, Perrin J, Orsini JC (1996) Neuronal responses to delta9-tetrahyrocannabinol in the solitary tract nucleus. Eur J Pharmacol 312:273–279.CrossRefPubMedGoogle Scholar
  42. Himmi T, Perrin J, El Ouazzani T, Orsini JC (1998) Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol 359:49–54.CrossRefPubMedGoogle Scholar
  43. Howlett AC, Barth F, Bonner TI, Cabral P, Casellaa G, Devane WA, Felder CC, Herkenham M, Mackie K, Martin B R, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54:161–202.CrossRefPubMedGoogle Scholar
  44. Iversen LL (2000) The Science of Marijuana. New York: Oxford University Press.Google Scholar
  45. Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I (1998) Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5HT) receptor. Biol Pharm Bull 21:224–226.PubMedGoogle Scholar
  46. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174:254–259.CrossRefPubMedGoogle Scholar
  47. Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, Klimberg VS (2006) Prevention of nausea and vomiting following breast surgery. Am J Surg 191:767–772.CrossRefPubMedGoogle Scholar
  48. Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 26:371–384.Google Scholar
  49. Limebeer CL, Parker LA (2000) Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: a rat model of nausea. J Exp Psychol Anim Behav Process 26:371–384.CrossRefPubMedGoogle Scholar
  50. Limebeer CL, Parker LA (2003) The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology 166:120–126.PubMedGoogle Scholar
  51. Limebeer CL, Parker, LA, Fletcher, P (2004) 5, 7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei interfere with lithium-induced conditioned gaping, but not conditioned taste avoidance, in rats. Behav Neurosci 118:1391–1399.CrossRefPubMedGoogle Scholar
  52. Limebeer CL, Hall G, Parker LA (2006) Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav 88:398–403.CrossRefPubMedGoogle Scholar
  53. Limebeer CL, Krohn JP, Rock EM, Cross-Mellor SK, Parker LA, Ossenkopp KP (2007) Exposure to a context previously associated with toxin (LiCl)- or motion-induced sickness elicits conditioned gaping in rats: evidence in support of a model of anticipatory nausea. Behav Brain Res (in press).Google Scholar
  54. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldman M (2000) The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritc therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9561–9566.CrossRefPubMedGoogle Scholar
  55. Matsuki N, Ueno S, Kaji T, Ishihara A, Wang CH, Saito H (1988) Emesis induced by cancer chemotherapeutic agents in the Suncus murinus: a new experimental model. Jpn J Pharmacol 48:303–306.CrossRefPubMedGoogle Scholar
  56. McCarthy LE, Borison HL (1981) Anti-emetic activity of N-methyllevonantrobil and naboline in cisplatin treated cats. J Clin Pharmacol 21:30S–37S.PubMedGoogle Scholar
  57. McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD (2005) The cannabinoid antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 180:286–293.CrossRefPubMedGoogle Scholar
  58. Meachum CL, Bernstein IL (1992) Behavioral conditioned responses to contextual and odor stimuli paired with LiCl administration. Physiol Behav 52:895–899.CrossRefPubMedGoogle Scholar
  59. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19S.PubMedGoogle Scholar
  60. Miner WJ, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497–499.PubMedGoogle Scholar
  61. Morrow GR, Dobkin PL (1988) Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: prevalence, etiology and behavioral interventions. Clin Psychol Rev 8:517–556.CrossRefGoogle Scholar
  62. Nesse R M, Carli T, Curtis GC, Kleinman PD (1980) Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 42:33–36.PubMedGoogle Scholar
  63. Parker LA (1982) Nonconsummatory and consummatory behavioral CRs elicited by lithium-paired and amphetamine-paired flavors. Learn Motiv 13:281–303.CrossRefGoogle Scholar
  64. Parker LA (1995) Rewarding drugs produce taste avoidance, but not taste aversion. Neurosci Biobehav Rev 19:143–151.CrossRefPubMedGoogle Scholar
  65. Parker LA (1998) Emetic drugs produce conditioned rejection reactions in the taste reactivity test. J Psychophysiol 12:3–13.Google Scholar
  66. Parker LA (2003) Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31:165–172.PubMedGoogle Scholar
  67. Parker LA, Kemp S (2001) Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport 12:749–751.CrossRefPubMedGoogle Scholar
  68. Parker LA, Mechoulam R (2003) Cannabinoid agonists and an antagonist modulate conditioned gaping in rats. Integr Physiol Behav Sci 38:134–146.Google Scholar
  69. Parker LA, Corrick ML, Limebeer CL, Kwiatkowska M (2002a) Amphetamine and morphine produce a conditioned taste and place preference in the house musk shrew (Suncus murinus). J Exp Psychol Anim Behav Process 28:75–82.Google Scholar
  70. Parker LA, Mechoulam R, Schlievert C (2002b) Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13:567–570.CrossRefPubMedGoogle Scholar
  71. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2003a) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacology 171:156–161.Google Scholar
  72. Parker LA, Mechoulam R, Shlievert C, Abbott L, Fudge ML, Burton P (2003b) Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 166:156–162.PubMedGoogle Scholar
  73. Parker LA, Limebeer CL, Kwiatkowska M (2005) Cannabinoids: effects on vomiting and nausea in animal models. In: Mechoulam R (ed.), Cannabinoids as Therapeutics. Basel: Birkhauser Verlag, pp. 183–200.CrossRefGoogle Scholar
  74. Parker LA, Kwiatkowska M, Mechoulam R (2006) Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87:61–71.CrossRefGoogle Scholar
  75. Pavlov IP (1927) Conditioned Reflexes (G.V. anrep, trans.).London: Oxford University Press.Google Scholar
  76. Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. Gut 48:859–867.CrossRefPubMedGoogle Scholar
  77. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North American Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295:761–775.CrossRefGoogle Scholar
  78. Reynolds DJM, Barber NA, Grahame-Smith DG, Leslie RA (1991) Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the antiemetic 5HT-3 receptor antagonist granisetron. Brain Res 565:321–336.CrossRefGoogle Scholar
  79. Rodriguez M, Lopez M, Symonds M, Hall G (2000) Lithium-induced context aversion in rats as a model of anticipatory nausea in humans. Physiol Behav 71:571–579.CrossRefPubMedGoogle Scholar
  80. Rudd JA, Naylor RJ (1996) An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118:209–214.PubMedGoogle Scholar
  81. Rudd JA, Jordan, CC, Naylor, RJ (1996) The action of the NK1 tachykinin receptor antagonist, CP 99, 994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119:931–936.PubMedGoogle Scholar
  82. Russo EB, Burnett, A, Hall B, Parker KK (2005) Agonist properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043.CrossRefPubMedGoogle Scholar
  83. Schlicker E, Kathman M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. TIPS 22:565–571.PubMedGoogle Scholar
  84. Schwartz RH, Beveridge RA (1994) Marijuana as an antiemetic drug: how useful is it today? Opinions from clinical oncologists. J Addict Dis 13:53–65.CrossRefPubMedGoogle Scholar
  85. Shannon HE, Martin WR, Silcox D (1978) Lack of antiemetic effect of S9-tetrahydrocannabinol in apomorphine-induced emesis in the dog. Life Sci 23:49–53.CrossRefPubMedGoogle Scholar
  86. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A, Malan P (2001) The cannabinoid agonist WIN 55, 212–2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94:882–886.CrossRefPubMedGoogle Scholar
  87. Sink KS, McLaughlin PJ, Brown C, Xu W, Fan P, Vemuri VK, Wood, JT, Makriyannis A, Parker LA, Salamone JD (2007) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (in press).Google Scholar
  88. Stockhorst U, Klosterhalfen S, Klosterhalfen W, Winkelmann M, Steingrueber HJ (1993) Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci 28:177–181.CrossRefPubMedGoogle Scholar
  89. Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RJ (2004) 6²-Azidohex-2²-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487:213–221.CrossRefPubMedGoogle Scholar
  90. Torii Y, Saito H, Matsuki N (1991) Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus Murinus. Jpn J Pharmacol 55:107–113.Google Scholar
  91. Tramer, MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:1–8.CrossRefGoogle Scholar
  92. Travers JB, Norgren R (1986) Electromyographic analysis of the ingestion and rejection of sapid stimuli in the rat. Behav Neurosci 100:544–555.CrossRefPubMedGoogle Scholar
  93. Tsukada H, Hirose T, Yokoyama A, Kurita Y (2001) Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for control of delayed cisplatin-induced emesis. Eur J Cancer 37:2398–2404.CrossRefPubMedGoogle Scholar
  94. Ueno S, Matsuki N, Saito H (1987) Suncus murinus: a new experimental model in emesis research. Life Sci 43:513–518.CrossRefGoogle Scholar
  95. Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG (1984) Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology 150:598–599.PubMedGoogle Scholar
  96. Van Belle S, Lichinitser M, Navari R, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, DeSmet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the slective neurokinin-1 antagonists, L-758, 298 and MK869. Cancer 94:3032–3041.CrossRefPubMedGoogle Scholar
  97. Van Sickle MD, Oland LD, HO W, Hillard CJ, Mackie K, Davison JS, Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121:767–774.CrossRefPubMedGoogle Scholar
  98. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) V9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:G566–G576.PubMedGoogle Scholar
  99. Van Sickle MD, Cuncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Linda A. Parker
    • 1
  • Cheryl L. Limebeer
  1. 1.Department of PsychologyUniversity of GuelphGuelphCanada

Personalised recommendations